Close Menu
Beverly Hills Examiner

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    WHOA: Treasury Secretary Scott Bessent Reveals Name of The Reckless Wall Street Journal Editor Who DOXXED Him, Allowing Iran to Target Him and His Entire Family (VIDEO) * The Gateway Pundit * by Cullen Linebarger

    November 15, 2026

    TechCrunch Mobility: The Nvidia backup plan for Chinas self-driving industry | TechCrunch

    November 15, 2026

    Black University of Mississippi students wrestle with forgiveness in wake of racist gestures

    November 15, 2026
    Facebook X (Twitter) Instagram
    Beverly Hills Examiner
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • Lifestyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Terms and Conditions
      • Privacy Policy
    Beverly Hills Examiner
    Home»Science»A Cutting-Edge Cancer Treatment May Cause Cancer. The FDA Is Investigating
    Science

    A Cutting-Edge Cancer Treatment May Cause Cancer. The FDA Is Investigating

    By AdminNovember 29, 2023
    Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    A Cutting-Edge Cancer Treatment May Cause Cancer. The FDA Is Investigating

    [ad_1]

    Scientists use harmless viruses to ferry and insert the new genetic material because of their natural ability to get inside cells. But the potential for these viruses to accidentally trigger another cancer has long been considered a theoretical risk. In its notice, the FDA said the use of these viruses may have played a role in patients developing secondary cancers.

    The downside of using viruses is that they tend to drop off their genetic cargo at a random place in a person’s genome. Depending on where this new genetic material integrates, it could potentially activate a nearby cancer gene. “The concern would be that somehow the new genetic material that you put into patients’ T cells can induce cancer in that cell, perhaps by where it gets inserted in the DNA,” Porter says.

    Because of this risk, the FDA currently requires that patients who receive CAR-T cell therapies be monitored for 15 years after treatment. In its notice on Tuesday, the agency suggested that “patients and clinical trial participants receiving treatment with these products should be monitored life-long for new malignancies.”

    Maksim Mamonkin, an associate professor of pathology and immunology at Baylor College of Medicine who is involved in several clinical trials of CAR-T cell therapies, says he is not aware of cases in which engineered T cells became cancerous in the dozens of patients treated there. But he says no therapy is risk-free. “It doesn’t mean it isn’t possible,” he says. “It cannot be ruled out that, just by chance, the CAR gene ends up in the wrong location in the genome.”

    Another explanation is that previous cancer treatments, including chemotherapy and radiation, played a role in the new T cell cancers patients developed. These treatments kill cancer cells, but they also damage DNA in healthy cells. In doing so, they can cause changes in cells that give rise to cancer later on.

    “Very often, cancer is more than just one mutation, more than one insult,” Porter says. “So you may damage the DNA with prior chemotherapy or radiation, making that cell more prone. Should it have another event, then it’s well on the way already to becoming a cancer cell.”

    A spokesperson for Novartis, which makes Kymriah, said that 10,000 patients have been treated with the therapy since its approval in 2017. The company has not seen any evidence to date that would change its confidence in the therapy’s risk-benefit profile. “As part of our continuous safety monitoring, Novartis has not identified a causal relationship between Kymriah and secondary malignancies,” a spokesperson told WIRED via email.

    A representative for Bristol Myers Squibb, which manufactures two approved CAR-T cell therapies, Abecma and Breyanzi, wrote that the company is aware of the FDA’s investigation. More than 4,700 patients have received the therapies, either in research trials or as commercial products. “To date, BMS has not observed any CAR-positive T-cell malignancy cases and therefore, we have not found a causal relationship between our products and secondary malignancies,” the spokesperson told WIRED by email.

    Johnson & Johnson, which makes another FDA-approved therapy, Carvykti, said through a spokesperson that the company is committed to the health and safety of patients. “We have shared our data with the FDA and are working with the agency as they assess this newly identified class-effect safety signal,” a spokesperson told WIRED in an email. More than 2,000 patients have been treated with Carvykti, they wrote.

    In yesterday’s statement, the FDA wrote that “the benefits of these products continue to outweigh their potential risks.”

    Porter agrees. “Clearly, this is concerning and we need more information,” he says. “But it’s likely to be a rare phenomenon.”

    [ad_2]

    Original Source Link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Email Reddit Telegram
    Previous ArticleBest Horror Movies On Netflix (December 2023)
    Next Article An AI Dreamed Up 380,000 New Materials. The Next Challenge Is Making Them

    RELATED POSTS

    Heres What We Know About the X-70 Fractal, NASAs Experimental New Plane

    November 10, 2026

    Scientists May Have Discovered a Massive Starless Galaxy

    November 9, 2026

    These Robotic Arms Are Powered by Algae. Watch How They Move

    November 9, 2026

    A 55-Year-Old Math Problem Was Solved—This Time by Humans

    November 8, 2026

    The American Dream Wasnt Built for Climate Change

    November 7, 2026

    The Cybertrucks Death Is Actually Great News for EVs

    November 6, 2026
    latest posts

    WHOA: Treasury Secretary Scott Bessent Reveals Name of The Reckless Wall Street Journal Editor Who DOXXED Him, Allowing Iran to Target Him and His Entire Family (VIDEO) * The Gateway Pundit * by Cullen Linebarger

    Treasury Secretary Scott Bessent revealed that an editor from the Wall Street Journal doxed his…

    TechCrunch Mobility: The Nvidia backup plan for Chinas self-driving industry | TechCrunch

    November 15, 2026

    Black University of Mississippi students wrestle with forgiveness in wake of racist gestures

    November 15, 2026

    Best Buy Gift Guide 2026: Best Tech Gifts From Sony, Sennheiser, HP and Amazon to Shop Online

    November 15, 2026

    SNL Weekend Update Mocks Donald Trumps Response to FAA Ground Stop

    November 15, 2026

    The ultimate adulting task: signing up for health insurance | Fortune

    November 15, 2026

    Listen to the River! Arrow for a Stone Heart Is a Poetic Hybrid Experience Told Through an Indigenous Lens

    November 15, 2026
    Categories
    • Books (1,609)
    • Business (6,514)
    • Cover Story (16)
    • Film (6,448)
    • Lifestyle (4,495)
    • Music (6,523)
    • Politics (6,499)
    • Science (5,854)
    • Technology (6,451)
    • Television (6,148)
    • Uncategorized (3)
    • US News (6,498)
    popular posts

    Sen. Cory Booker Leads By Disrupting The Senate For As Long As He Can Stand To Protest Trump

    [ad_1] PoliticusUSA is ad-free and refusing to bend the knee. Please consider supporting us by…

    North Carolina’s Lieutenant Governor Takes Sexism To Biblical New Low

    June 7, 2022

    OpenAI releases new image model as it races to outpace Google’s Nano Banana amid company Code Red

    December 16, 2025

    Could This Harry Potter Theory Explain The Horcrux’s Missing Link?

    November 26, 2022
    Archives
    Browse By Category
    • Books (1,609)
    • Business (6,514)
    • Cover Story (16)
    • Film (6,448)
    • Lifestyle (4,495)
    • Music (6,523)
    • Politics (6,499)
    • Science (5,854)
    • Technology (6,451)
    • Television (6,148)
    • Uncategorized (3)
    • US News (6,498)
    About Us

    We are a creativity led international team with a digital soul. Our work is a custom built by the storytellers and strategists with a flair for exploiting the latest advancements in media and technology.

    Most of all, we stand behind our ideas and believe in creativity as the most powerful force in business.

    What makes us Different

    We care. We collaborate. We do great work. And we do it with a smile, because we’re pretty damn excited to do what we do. If you would like details on what else we can do visit out Contact page.

    Our Picks

    The ultimate adulting task: signing up for health insurance | Fortune

    November 15, 2026

    Listen to the River! Arrow for a Stone Heart Is a Poetic Hybrid Experience Told Through an Indigenous Lens

    November 15, 2026

    Man Who Allegedly Tried to Assassinate Trump at WHCA Dinner Now Faces Additional Charge of Terrorism * The Gateway Pundit * by Mike LaChance

    November 15, 2026
    © 2026 Beverly Hills Examiner. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms & Conditions and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT